These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 32910349)

  • 41. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
    Ocello A; La Rosa S; Fiorini F; Randone S; Maccarrone R; Battaglia G; Granata A
    G Ital Nefrol; 2019 Jul; 36(4):. PubMed ID: 31373464
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
    Barrera-Chimal J; Lima-Posada I; Bakris GL; Jaisser F
    Nat Rev Nephrol; 2022 Jan; 18(1):56-70. PubMed ID: 34675379
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Finerenone in diabetic kidney disease: A systematic review and critical appraisal.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Oct; 16(10):102638. PubMed ID: 36223666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
    Haller H
    Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Role of Finerenone in the Management of Diabetic Nephropathy.
    Veneti S; Tziomalos K
    Diabetes Ther; 2021 Jul; 12(7):1791-1797. PubMed ID: 34050896
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
    Pitt B; Agarwal R; Anker SD; Ruilope LM; Rossing P; Ahlers C; Brinker M; Joseph A; Lambelet M; Lawatscheck R; Filippatos GS;
    JAMA Netw Open; 2022 Oct; 5(10):e2236123. PubMed ID: 36287567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.
    Filippatos G; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Kim SY; Nowack C; Palombo G; Kolkhof P; Kimmeskamp-Kirschbaum N; Pieper A; Pitt B
    Eur Heart J; 2016 Jul; 37(27):2105-14. PubMed ID: 27130705
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook.
    Lorente-Ros M; Aguilar-Gallardo JS; Shah A; Narasimhan B; Aronow WS
    Expert Opin Pharmacother; 2022 Oct; 23(15):1737-1751. PubMed ID: 36262014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
    Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
    Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
    Raj R
    Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.
    Kawanami D; Takashi Y; Muta Y; Oda N; Nagata D; Takahashi H; Tanabe M
    Front Pharmacol; 2021; 12():754239. PubMed ID: 34790127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
    Young MJ; Kanki M; Karthigan N; Konstandopoulos P
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
    Sato N; Ajioka M; Yamada T; Kato M; Myoishi M; Yamada T; Kim SY; Nowack C; Kolkhof P; Shiga T;
    Circ J; 2016 Apr; 80(5):1113-22. PubMed ID: 27074824
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of mineralocorticoid receptor antagonists in kidney diseases.
    Patel V; Joharapurkar A; Jain M
    Drug Dev Res; 2021 May; 82(3):341-363. PubMed ID: 33179798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
    Bramlage P; Swift SL; Thoenes M; Minguet J; Ferrero C; Schmieder RE
    Eur J Heart Fail; 2016 Jan; 18(1):28-37. PubMed ID: 26634965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges.
    Yang P; Huang T; Xu G
    Metabolism; 2016 Sep; 65(9):1342-9. PubMed ID: 27506741
    [No Abstract]   [Full Text] [Related]  

  • 57. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development.
    Kolkhof P; Bärfacker L
    J Endocrinol; 2017 Jul; 234(1):T125-T140. PubMed ID: 28634268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease.
    Agarwal R; Pitt B; Palmer BF; Kovesdy CP; Burgess E; Filippatos G; Małyszko J; Ruilope LM; Rossignol P; Rossing P; Pecoits-Filho R; Anker SD; Joseph A; Lawatscheck R; Wilson D; Gebel M; Bakris GL
    Clin Kidney J; 2023 Feb; 16(2):293-302. PubMed ID: 36864892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
    J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study.
    Blankenburg M; Fett AK; Eisenring S; Haas G; Gay A
    BMC Nephrol; 2019 May; 20(1):171. PubMed ID: 31096928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.